Serratiopeptidase vs Standard Care After Mandibular Third Molar Surgery

A randomized controlled trial (NCT07543146) has been registered on ClinicalTrials.gov to evaluate the effectiveness of serratiopeptidase — an enzymatic anti-inflammatory agent — versus no intervention (standard postoperative care) following the surgical extraction of mesioangular mandibular third molars. The study's primary endpoints are postoperative mouth opening, facial swelling, and trismus (jaw stiffness).

For healthcare providers, clinical investigators, and pharmaceutical companies involved in surgical pharmacology, this registry entry signals ongoing interest in serratiopeptidase as an adjunct therapy for managing postextraction inflammation. The trial does not yet constitute an approved indication or regulatory finding; no compliance obligations arise from this registration.